NRG-BN013: PHASE III TRIAL OF SINGLE FRACTION STEREOTACTIC RADIOSURGERY (SRS) VERSUS FRACTIONATED SRS (FSRS) FOR INTACT BRAIN METASTASES NRG-BN013: PHASE III TRIAL OF SINGLE FRACTION STEREOTACTIC RADIOSURGERY (SRS) VERSUS FRACTIONATED SRS (FSRS) FOR INTACT BRAIN METASTASES NRG-BN013 is an unblinded, randomized phase III trial to determine if the time to local failure is significantlylonger with FSRS compared to SRS in patients with intact brain metastasis.NCT06500455Eva Galvan MD

Phase III Randomized Study Testing Non-inferiority of Short-course Ultra-hypofractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) For Stage II-IIIB, Extremity, Resectable Soft Tissue SarcomaPhase III Randomized Study Testing Non-inferiority of Short-course Ultra-hypofractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) For Stage II-IIIB, Extremity, Resectable Soft Tissue SarcomaWe propose a clinical trial comparing standard radiation (RT-25) to ultra-hypofractionated radiation (UHRT-5). If negative, this trial would stop participants from being treated, as many are, with an inferior regimen. If positive, this trial would establish a new standard of careClinicalTrials.gov registration not requiredEva Galvan MD

A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone.NCT06479135Zohra Nooruddin MD